David Meek, Mirati Therapeutics CEO (Photographer: Marlene Awaad/Bloomberg via Getty Images)

#ES­MO22: Mi­rati vs. Am­gen: Scrap­py KRAS G12C con­tender out­per­forms its gi­ant ri­val in col­orec­tal can­cer

PARIS — This week­end at ES­MO, the KRAS bat­tle be­tween Am­gen and its pesky biotech ri­vals at Mi­rati will con­tin­ue with new slices of com­bo da­ta for ad­vanced cas­es of col­orec­tal can­cer. And once again, Mi­rati will get in with a sol­id punch.

Am­gen has up­dat­ed com­bi­na­tion da­ta on its ap­proved pi­o­neer Lumakras and its EGFR in­hibitor Vectibix with a 30% over­all re­sponse rate — way bet­ter than the mea­ger 9.3% it post­ed ear­li­er for the monother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.